July 7, 2008
Leading Worldwide Cause of Cardiovascular Disease May Be Modified By Diet
NASHVILLE, Tenn., July 7 /PRNewswire/ -- A new article indicates that an increased intake in minerals such as potassium, and possibly magnesium and calcium by dietary means may reduce the risk of high blood pressure and decrease blood pressure in people with hypertension. A high intake of these minerals in the diet may also reduce the risk of coronary heart disease and stroke. These findings are published in a supplement appearing with the July issue of The Journal of Clinical Hypertension.
Potassium, specifically, has been hypothesized as one reason for the low cardiovascular disease rates in vegetarians, as well as in populations consuming primitive diets (generous in potassium and low in sodium). In isolated societies consuming diets high in fruits and vegetables, hypertension affects only 1 percent of the population, whereas in industrialized countries which consume diets high in processed foods and large amounts of dietary sodium, 1 in 3 persons have hypertension. Americans consume double the sodium and about half of the potassium that is recommended by current guidelines.According to the paper, if Americans were able to increase their potassium intake, the number of adults with known hypertension with blood pressure levels higher than 140/90 mm Hg might decrease by more than 10 percent and increase life expectancy. Similar studies show that diets high in magnesium (at least 500 to 1,000 mg/d) and calcium (more than 800 mg/d) may also be associated with both a decrease in blood pressure and risk of developing hypertension. Data regarding these minerals, however, are not definitive.
"If we were to achieve the correct potassium/sodium ratio through dietary means, there would be less hypertension and cardiovascular disease in the population as a whole," says Mark C. Houston, M.D., author of the study.
Diets that emphasize fruits, vegetables and low-fat dairy products, including the landmark Dietary Approaches to Stop Hypertension (DASH) trial, have been advocated by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the American Heart Association, the European Society of Hypertension, the World Health Organization and the British Hypertension Society.
Hypertension is the leading cause of cardiovascular disease, affecting approximately 1 billion individuals worldwide and is the most common reason for visits to physician's offices and the primary reason for prescription drug use.
More than 70 million Americans, or nearly 1-in-3 adults, are estimated to have hypertension, but fewer than 50 percent achieve blood pressure control. Nearly 70 million more adults have high-normal or pre-hypertensive blood pressure levels of 120/80 mm Hg to 130/85 mm Hg, and 90 percent of adults will probably develop hypertension by age 65. Poor blood pressure control is a major challenge for patients with diabetes and chronic kidney disease. Despite major advances in the prevention and treatment of hypertension over the past decades, with a decrease of more than 60 percent in hypertension-related strokes, hypertension remains an important public health challenge.
This study is published in The Journal of Clinical Hypertension. Media wishing to receive a PDF of this article may contact [email protected]
Mark C. Houston, M.D. is Associate Clinical Professor of Medicine at the Vanderbilt University School of Medicine and Director, Hypertension Institute and Vascular Biology of Nashville. Dr. Houston can be reached for questions at [email protected]
The Journal of Clinical Hypertension is a peer-reviewed, monthly publication that serves family practitioners, internists, and cardiologists by providing objective, up-to-date information and practical recommendations on the treatment of hypertension. As newer studies are completed, they are summarized and critiqued. Reviews of recent publications in other journals and original papers that focus on the clinical management of hypertension are featured. JCH is the official journal of the American Society of Hypertension, Inc. For more information, please visit http://www.blackwell-synergy.com/loi/jch.
Wiley-Blackwell was formed in February 2007 as a result of the acquisition of Blackwell Publishing Ltd. by John Wiley & Sons, Inc., and its merger with Wiley's Scientific, Technical, and Medical business. Together, the companies have created a global publishing business with deep strength in every major academic and professional field. Wiley-Blackwell publishes approximately 1,400 scholarly peer-reviewed journals and an extensive collection of books with global appeal. For more information on Wiley-Blackwell, please visit http://www.blackwellpublishing.com/ or http://interscience.wiley.com/.
Contact: Sean Wagner 781-388-8550 [email protected]ellpublishing.net
Journal of Clinical Hypertension
CONTACT: Sean Wagner for the Journal of Clinical Hypertension,+1-781-388-8550, [email protected]
Web site: http://www.blackwell-synergy.com/loi/jchhttp://www.blackwellpublishing.com/http://interscience.wiley.com/